12/19
07:02 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/18
08:05 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
12/18
08:00 am
sabs
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Low
Report
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
12/17
08:43 am
sabs
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]
Medium
Report
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]
12/17
08:00 am
sabs
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Medium
Report
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
12/8
08:00 am
sabs
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
High
Report
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
11/22
02:11 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
11/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/12
01:30 pm
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:15 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/4
08:30 am
sabs
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
Medium
Report
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
11/4
08:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences
9/20
01:09 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree